Prognostic Significance of ctDNA in HL
ConditionPrognostic Cancer Model
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInterni hematologicka klinika FNKV
About this trial
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.
Eligibility criteria
Qualifiers
Patients ≥ 18 years with newly histologically confirmed classical Hodgkin lymphoma (cHL) will be enrolled
signing the informed consent
Disqualifiers
Pacients without signing the informed consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 6 trial groups6
Trial groupsSee each trial group below.
Sponsors and collaborators
Interni hematologicka klinika FNKV
Lead sponsor
Charles University, Czech Republic
Collaborator
General University Hospital, Prague
Collaborator
University Hospital Olomouc
Collaborator
University Hospital Hradec Kralove
Collaborator
University Hospital, Motol
Collaborator
Source ClinicalTrials.gov